1. Academic Validation
  2. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model

  • Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3151-3156. doi: 10.1073/pnas.1620262114.
Emilie A Chapeau 1 Agnieszka Gembarska 2 Eric Y Durand 2 Emeline Mandon 2 Claire Estadieu 2 Vincent Romanet 2 Marion Wiesmann 2 Ralph Tiedt 3 Joseph Lehar 4 Antoine de Weck 2 Roland Rad 5 6 Louise Barys 3 Sebastien Jeay 2 Stephane Ferretti 2 Audrey Kauffmann 2 Esther Sutter 7 Armelle Grevot 7 Pierre Moulin 7 Masato Murakami 2 William R Sellers 4 Francesco Hofmann 2 Michael Rugaard Jensen 2
Affiliations

Affiliations

  • 1 Oncology Disease Area, Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland; emilie.chapeau@novartis.com.
  • 2 Oncology Disease Area, Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.
  • 3 Oncology Translational Research, Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.
  • 4 Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA 02139.
  • 5 Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany.
  • 6 German Cancer Research Center (DKFZ) and German Cancer Consortium, 69120 Heidelberg, Germany.
  • 7 Preclinical Safety, Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.
Abstract

Inhibitors of double minute 2 protein (MDM2)-tumor protein 53 (TP53) interaction are predicted to be effective in tumors in which the TP53 gene is wild type, by preventing TP53 protein degradation. One such setting is represented by the frequent CDKN2A deletion in human Cancer that, through inactivation of p14ARF, activates MDM2 protein, which in turn degrades TP53 tumor suppressor. Here we used piggyBac (PB) transposon insertional mutagenesis to anticipate resistance mechanisms occurring during treatment with the MDM2-TP53 inhibitor HDM201. Constitutive PB mutagenesis in Arf-/- mice provided a collection of spontaneous tumors with characterized insertional genetic landscapes. Tumors were allografted in large cohorts of mice to assess the pharmacologic effects of HDM201. Sixteen out of 21 allograft models were sensitive to HDM201 but ultimately relapsed under treatment. A comparison of tumors with acquired resistance to HDM201 and untreated tumors identified 87 genes that were differentially and significantly targeted by the PB transposon. Resistant tumors displayed a complex clonality pattern suggesting the emergence of several resistant subclones. Among the most frequent alterations conferring resistance, we observed somatic and insertional loss-of-function mutations in transformation-related protein 53 (Trp53) in 54% of tumors and transposon-mediated gain-of-function alterations in B-cell lymphoma-extra large (Bcl-xL), Mdm4, and two TP53 family members, resulting in expression of the TP53 dominant negative truncations ΔNTrp63 and ΔNTrp73. Enhanced Bcl-xL and MDM4 protein expression was confirmed in resistant tumors, as well as in HDM201-resistant patient-derived tumor xenografts. Interestingly, concomitant inhibition of MDM2 and Bcl-xL demonstrated significant synergy in p53 wild-type cell lines in vitro. Collectively, our findings identify several potential mechanisms by which TP53 wild-type tumors may escape MDM2-targeted therapy.

Keywords

MDM2 inhibitor; cancer; drug resistance; piggyBac screen.

Figures
Products